Introduction: Rhabdomyosarcoma (RMS) is a malignant soft-tissue tumor arising from striated muscle cells. It accounts for 60% - 70% of malignant mesenchymal tumors and 5% of pediatric cancers. Two-thirds of these cancers are diagnosed in children under 6 years of age, with a slight male predominance. Materials and Methods: This is a retrospective descriptive study of 10 cases of RMS collected in the pediatric hematology and oncology department of the Oujda university hospital, over a 5-year period, running from January 2018 to December 2022. Results: The median age at diagnosis was 3 years, with a sex ratio of 1. The mean time to diagnosis was 2 months. The most common site was the head and neck (50%), followed by the genitourinary tract (20%), the extremities (20%) and finally the abdomen (10%). The most frequent mode of discovery was a mass or swelling found in 90% of patients (all sites included), followed by exophthalmos in 30% of cases. At the diagnostic stage, CT scans were performed in 70% of cases and MRI in 5 patients (50%). Histological diagnosis was determined by immunohistochemical pathology in all our patients, with a predominance of embryonal (70%) versus alveolar (20%) and spindle cell types (10%). All patients underwent an extension workup, and a cervico-thoraco-abdominopelvic CT was performed in all patients (100%); MRI was performed in 2 patients (20%); lymph node involvement was present in 5 patients (50%). Metastases at the time of diagnosis were noted in only 1 patient (10%), who simultaneously presented with two metastatic sites; testicular and abdominal wall. Sixty percent of patients presented with advanced disease (high risk) and 40% with standard risk. Chemotherapy was used in all patients (100%), with upfront tumor resection performed in 40%. Fifty percent of patients received radiotherapy at a mean dose of 43 Gy, with the orbit the most frequently irradiated area (30%). All patients underwent CTscan and/or MRI and/or ultrasound surveillance. Follow-up during and after treatment was marked by complete remission in 8patients, loss of sight in one patient, and one patient died as a result of progressive disease. Conclusion: RMS is a malignant tumor of striated muscle. The epidemiological and clinical features of this tumor in our study are generally similar to those described in the literature. Management of these tumors requires multidisciplinary collaboration involving oncopediatric, radiologist, pediatric surgeon,
References
[1]
Chen, E., Ricciotti, R., Futran, N. and Oda, D. (2017) Head and Neck Rhabdomyosarcoma: Clinical and Pathologic Characterization of Seven Cases. Head and Neck Pathology, 11, 321-326. https://doi.org/10.1007/s12105-016-0771-0
[2]
Amer, K.M., Thomson, J.E., Congiusta, D., et al. (2019) Epidemiology, Incidence, and Survival of Rhabdomyosarcoma Subtypes: SEER and ICES Database Analysis. Journal of Orthopaedic Research, 37, 2226-2230. https://doi.org/10.1002/jor.24387
[3]
Dasgupta, R. and Rodeberg, D.A. (2012) Update on Rhabdomyosarcoma. Seminars in Pediatric Surgery, 21, 68-78. https://doi.org/10.1053/j.sempedsurg.2011.10.007
[4]
D’Andon, A., Hartmann, O. and Vassal, G. (2003) Tumeursmésenchymateusesmalignesousarcomes des parties molles. Institute Gustave Roussy, Mai.
[5]
Sommelet, D., Pinkerton, R., Brunat-Mentigny, M., Farsi, F., et al. (1998) Standards, Options and Recommendations (SOR) for Clinical Care of Rhabdomyosarcoma (RMS) and Other Soft Tissue Sarcoma in Children. Federation of the French Cancer Centers. French Society of Pediatric Oncology. Bulletin du Cancer, 85, 1015-1042.
[6]
Dagher, R. and Helman, L. (2022) Rhabdomyosarcoma: An Overview. The Oncologist, 4, 34-44. https://doi.org/10.1634/theoncologist.4-1-34
[7]
Crucis, A., Richer, W., Brugières, L., Bergeron, C., Marie-Cardine, A., Stephan, J.L., Bourdeaut, F., et al. (2015) Rhabdomyosarcomas in Children with Neurofibromatosis Type I: A National Historical Cohort. Pediatric Blood & Cancer, 62, 1733-1738. https://doi.org/10.1002/pbc.25556
[8]
Chisholm, J.C., Marandet, J., Rey, A., et al. (2011) Prognostic Factors after Relapse in Nonmetastatic Rhabdomyosarcoma: A Nomogram to Better Define Patients Who Can Be Salvaged with Further Therapy. Journal of Clinical Oncology, 29, 1319-1325. https://doi.org/10.1200/JCO.2010.32.1984
[9]
Koscielniak, E., Harms, D., Henze, G., et al. (1999) Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. Journal of Clinical Oncology, 17, 3706-3719. https://doi.org/10.1200/JCO.1999.17.12.3706
[10]
Hessissen, L., Kanouni, L., Kili, A., Nachef, M.N., El Khorassani, M., Benjaafar, N., Khattab, M. and El Gueddari Bel, K. (2010) Pediatric Rhabdomyosarcoma in Morocco. Pediatric Blood and Cancer, 54, 25-28. https://doi.org/10.1002/pbc.22173
[11]
Mcdowell, H.P. (2003) Update on Childhood Rhabdomyosarcoma. Archives of Disease in Childhood, 88, 354-357. https://doi.org/10.1136/adc.88.4.354
[12]
Leaphart, C. and Rodeberg, D. (2007) Pediatric Surgicaloncology: Management of Rhabdomyosarcoma. Surgicaloncology, 16, 173-185. https://doi.org/10.1016/j.suronc.2007.07.003
[13]
Jaba, S., et al. (2020) Apport de l’imageriedans le diagnostic et le suivi post-thérapeutique des rhabdomyosarcome de la fosse infra-temporale chez l’adulte. Journal de Neuroradiologie, 47, 126-127. https://doi.org/10.1016/j.neurad.2020.01.067
[14]
Grufferman, S., et al. (2009) Prenatal X-Ray Exposure and Rhabdomyosarcoma in Children: A Report from the Children’s Oncology Group. Cancer Epidemiology, Biomarkers & Prevention, 18, 1271-1276. https://doi.org/10.1158/1055-9965.EPI-08-0775
[15]
Crist, W., et al. (1995) The Third Intergroup Rhabdomyosarcoma Study. Journal Clinical Oncology, 13, 610-630. https://doi.org/10.1200/JCO.1995.13.3.610
[16]
Dziuba, I., et al. (2018) Rhabdomyosarcoma in Children—Current Pathologic and Molecular Classification. Polish Journal of Pathology, 69, 20-32.
[17]
Reilly, B.K., et al., (2015) Rhabdomyosarcoma of the Head and Neck in Children: Review and Update. International Journal Pediatric Otorhinolaryngology, 79, 1477-1483. https://doi.org/10.1016/j.ijporl.2015.06.032
[18]
Tagami, Y., et al. (2019) Spindle Cell Rhabdomyosarcoma in a Lumbar Vertebra with FUS-TFCP2 Fusion. Pathology—Respond Practice, 215, Article ID: 152399. https://doi.org/10.1016/j.prp.2019.03.027
[19]
Sherr, C.J. (1996) Cancer Cell Cycles. Science, 274, 1672-1677. https://doi.org/10.1126/science.274.5293.1672
[20]
Philippe-Chomette, P., Orbach, D., Brisse, H., Aigrain, Y., Berrebic, D. and El Ghoneimi, A. (2006) Rhabdomyosarcomes du sinus urogénital de l’enfant. Annalesd’urologie, 40, 280-296. https://doi.org/10.1016/j.anuro.2006.08.002
[21]
Dantonello, T.M., Int-Veen, C., Schuck, A., et al. (2013) Survival Following Disease Recurrence of Primary Localized Alveolar Rhabdomyosarcoma. Pediatric Blood & Cancer, 60, 1267-1273. https://doi.org/10.1016/j.anuro.2006.08.002
[22]
Neville, H.L., Andrassy, R.J., Link, M.P., et al. (2000) Preoperative Staging: Prognostic Factors and Outcome for Extremity Rhabdomyosarcoma: A Preliminary Report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). Journal of Pediatric Surgery, 35, 317-321. https://doi.org/10.1016/S0022-3468(00)90031-9
[23]
Wiener, E.S., Anderson, J.R., Ojimba, J.I., et al. (2001) Controversies in the Management of Paratesticular Rhabdomyosarcoma: Is Staging Retroperitoneal Lymph Node Dissection Necessary for Adolescents with Resected Paratesticular Rhabdomyosarcoma? Seminars in Pediatric Surgery, 10, 146-152. https://doi.org/10.1053/spsu.2001.24695